• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Elsevier's 2024 Intravenous Medications

Elsevier's 2024 Intravenous Medications

A Handbook for Nurses and Health Professionals

9780443118838
260.76 zł
221.65 zł Save 39.11 zł Tax included
Lowest price within 30 days before promotion: 221.65 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Find the essential information you need to safely administer more than 400 intravenous drugs! For nearly 50 years, Elseviers Intravenous Medications:: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2024 edition are 8 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.

Product Details
Elsevier
94095
9780443118838
9780443118838

Data sheet

Publication date
2023
Issue number
40
Cover
soft binded
Pages count
1376
Weight (g)
1610
  • Evolve website information General Dilution Charts How to Use This Book Preface Format and Content of Intravenous Medications Key to Abbreviations Important IV Therapy Facts Resources Preparation and Administration of Injectable Drugs IV Drugs Appendix A: Recommendations for the Safe Use and Handling of Cytotoxic Drugs Appendix B: FDA Pregnancy Categories Appendix C: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Appendix D: Information for Patients Receiving Immunosuppressive Agents Appendix E: Recently Approved Drugs Index

Comments (0)